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Abstract
Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS)
pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations
analyses were performed at baseline and during the therapy. Results were then correlated to clinical outcome, overall
survival (OS), leukemia-free-survival (LFS) and response to therapy. Collectively, 34/44 patients were considered evaluable
for response, with an overall response rate of 76.25% (26/34 cases): 17 patients showed a durable response, 9 patients early
lost response and 8 patients never responded. The most frequently mutated genes were ASXL1, TET2, RUNX1, and SRSF2.
All patients early losing response, as well as cases never responding, acquired the same 3 point mutations during therapy,
affecting respectively PIK3CD (D133E), AKT3 (D280G), and PLCG2 (Q548R) genes, that regulate cell proliferation and
differentiation. Moreover, Kaplan–Meier analyses revealed that this mutated cluster was significantly associated with a
shorter OS, LFS, and duration of response. All in all, a common mutated cluster affecting 3 inositide-specific genes is
significantly associated with loss of response to azacitidine and lenalidomide therapy in higher risk MDS. Further studies are
warranted to confirm these data and to further analyze the functional role of this 3-gene cluster.
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous
group of hematological malignancies characterized by
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peripheral blood cytopenia and a variable risk of evolution
into acute myeloid leukemia (AML) [1]. MDS frequently
show mutations in genes involved in RNA splicing (e.g.,
SF3B1, SRSF2, U2AF1, ZRSR2; approximately 40–60%
of patients) [2, 3], DNA methylation (i.e., DNMT3A, TET2,
IDH1, IDH2; approximately 30–40%) or chromatin remo-
delling (i.e., ASXL1, EZH2; approximately 15–25%), that
are retrieved at diagnosis or can be specifically acquired
during follow-up [4, 5]. For instance, not only ASXL1
mutations are associated with impaired hematopoiesis and
are predictive of a poor outcome [6, 7], but also TP53,
EZH2, SF3B1, and SRSF2 mutations have been recognized
as being unfavorable for survival [8–10]. Moreover, specific
gene mutations, such as those affecting TET2, have been
associated with a favorable response to azacitidine [11],
while the acquisition of TP53 or NRAS mutations has
recently been related to resistance to lenalidomide [12, 13].
Epigenetic therapy is a first-line approach for MDS
patients at higher risk of AML progression, as it delays the
AML progression and improves the overall survival (OS)
[14, 15]. Also lenalidomide is widely used in MDS patients,
above all in those showing the deletion of the long arm of
chromosome 5 [del(5q)]. However, for the MDS patients
that are refractory or not suitable to the conventional stra-
tegies, the combination of these two drugs could be effec-
tive and is thus now clinically investigated [16, 17].
At a molecular level, azacitidine induces hypomethylation
of critical genes implicated in cell proliferation and myeloid
differentiation, such as those of the nuclear inositide signal-
ling pathways [18]. On the other hand, lenalidomide inhibits
cell proliferation by inducing the cereblon-dependent ubi-
quitination and degradation of casein kinase 1α [19]. More-
over, lenalidomide inhibits the activation of ERK and Akt-
dependent pathways, inducing cell apoptosis and affecting the
phosphatidylinositol (PI)-specific metabolism [20, 21].
Inositide-dependent signaling regulation is important
in hematological malignancies [22–24]. Phosphoinositide-
phospholipase C (PI-PLC) enzymes, such as PI-
PLCgamma2 and PI-PLCbeta1, are important players of
the signal transduction pathways [25–27]. Indeed, PI-
PLCgamma2 is mapped on chromosome 16q23.3 and
participates in cell proliferation and myeloid differentia-
tion [28]. Also PI-PLCbeta1, which is localized on the
20p arm, is involved in cell cycle [29] and hematopoietic
regulation, particularly in MDS [30, 31]. In fact, PI-
PLCbeta1 increased expression has been associated with a
positive response to azacitidine in MDS [32–35] and has
also been inversely correlated to Akt activation [36]. Also
Akt and PI3K-dependent signalling pathways play
essential roles in hematological malignancies [37]. There
are currently three known members of the Akt protein
family, namely Akt1, Akt2, and Akt3, each encoded by
a different gene [38]. These isoforms share a similar
N-terminal Pleckstrin-homology (PH) domain and a cen-
tral serine-threonine kinase domain, and their amino acid
sequences are highly conserved [39]. Of note, isoform-
specific Akt deregulation is frequently observed in dif-
ferent types of cancer. For instance, Akt3 impairment has
been associated with multiple myeloma [40], and de novo
Philadelphia chromosome-positive AML frequently show
mutations of AKT3 and PIK3CD genes [41]. Indeed, the
immune and leukocyte-restricted p110delta subunit of
phosphatidylinositol-3-kinase (PI3K) [42], whose gene is
PIK3CD, plays an important role in cell proliferation and
has been proposed as a potential target in the treatment of
AML [43, 44]. Moreover, recent studies showed that
PIK3CD germline mutations in B-cells can lead to either
gain or loss of function of PI3Kdelta, resulting in immune
dysregulation [45–47].
Stemming from these data, in the present study we fur-
ther investigated the role of azacitidine and lenalidomide
therapy in MDS, focusing on the effect of the treatment on
cancer myeloid and inositide-specific gene mutations. The
acquisition of specific gene mutations during therapy might
indeed be associated with MDS clinical outcome or therapy
response, but it could also lead to a better comprehension of
the mechanisms underlying the MDS pathogenesis and the
effect of therapy.
Methods
Patient characteristics
Bone marrow (BM) and peripheral blood (PB) samples were
obtained from 44 higher risk MDS patients [48, 49] who had
given informed consent according to the Declaration of
Helsinki (Table 1 and Supplementary Table 1). All samples
came from several Italian hematological centers and were
centralized at the Institute of Hematology “L. and A.
Seràgnoli”, Policlinico Sant’Orsola–Malpighi Hospital,
Bologna, Italy. Further details can be found in the Supple-
mentary Information.
Patient treatment and evaluation of response
Patients were treated with azacitidine (75 mg/m2/die for
7 days every 28 days) and lenalidomide (10 mg/day, days
1–21 or 6–21, orally) every 4 weeks. The response to
treatment and the clinical outcome were evaluated accord-
ing to the revised International Working Group (IWG)
response criteria [50] (Table 1 and Supplementary Table 1).
Further details can be found in the Supplementary
Information.
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Isolation of mononuclear cells and genomic DNA
extraction
For in vitro experiments, BM and PB mononuclear cells
were isolated at the time of diagnosis and during the ther-
apy, as described in the Supplementary Information.
Illumina and Ion Torrent next-generation
sequencing
The mutational profile of 32 recurrently mutated genes in
myeloid malignancies was determined using an Illumina
TruSeq Custom Amplicon next-generation sequencing gene
panel (Supplementary Table 2) and the TruSeq Amplicon
2.0 BaseSpace app workflow [51] (Illumina, San Diego,
CA, USA). 31 inositide-specific point mutations and small
indels (Supplementary Table 3) were examined using the
Ion Torrent S5 with an Ion AmpliSeq™ On-demand Panel
(Thermo Fisher Scientific, Whaltam, MA, USA). Sequen-
cing alignment was viewed by the Integrative Genomics
Viewer Software (Broad Institute, Cambridge, MA, USA)
using the Human Genome Build 19 (Hg19) as reference
[52]. Further details can be found in the Supplementary
Information.
Statistical analyses
All statistical analyses were performed using the GraphPad
Prism 5.0 Software (GraphPad Software, La Jolla, CA,
USA), as described in the Supplementary Information.
Results
Patient outcomes
Between March 2013 and December 2017, forty-four
patients diagnosed with high-risk MDS were treated with
a combination of azacitidine and lenalidomide (Table 1).
The median follow-up was 15 months (range 2–54 months).
Thirty-one patients reached at least six cycles of therapy
(T6) and were clinically evaluable for response. Moreover,
three patients showed a disease progression or hematologic
improvement before T4 and were evaluated for response
too, so that 34 cases were clinically evaluated for response.
According to the revised IWG criteria [50], the overall
response rate (ORR) was 76.5% (26/34 cases): CR (8/34,
23.5%), PR (1/34, 2.9%), marrow CR (mCR, 3/34, 8.8%),
HI (8/34, 23.5%), HI+mCR (6/34, 17.6%), whereas 6/34
patients (17.6%) had a stable disease and 2/34 cases (5.9%)
had a disease progression. Among the patients evaluated for
response, 13 patients showed a first positive response within
T4 and maintained it at T8 and after (good responders, GR);
9 patients showed a positive response within T4 and lost
response at T8 (transient responders, TR); 4 patients
responded after T4 and maintained the response at T8 (late
responders, LR); 8 patients never responded (non respon-
ders, NR).
Illumina gene mutation analyses
Paired samples (pre- and post-treatment) were tested for
mutations in genes that are recurrently mutated in myeloid
malignancies. As the quality and quantity of DNA for each
sample was critical, only 30/34 samples were tested at baseline
and during the therapy (Table 2): at T4 (n= 2), T6 (n= 2), T7
(n= 2), T8 (n= 19) and T10 (n= 4), while 1 sample was
tested at T4 and T8 (Table 2). Three of 30 patients showed no
mutations either at baseline or during therapy (they were tested
at baseline and T6, T7, and T10), while all other patients (27/
30) had at least one mutation (Table 2). In this latter group of
patients, two genes (NRAS and CEBPA), in two patients,
acquired specific mutations only during the therapy, while all
other genes were mutated in all 27 patients both at baseline
and during the treatment, showing different VAFs between
baseline and treatment. Remarkably, all samples showing a
statistically significant decreasing VAF during therapy for all
variants, as compared to baseline (n= 7), showed a favorable
response to therapy (3 CR, 1 mCR, 1 HI+mCR, 1 PR, 1 HI).
Conversely, none of the patients with SD (n= 7) showed a
major decreasing VAF during therapy for all variants, as
compared to baseline. All other patients had similar VAFs
between baseline and therapy or showed a mixed behavior for
all the variants identified (n= 13). Collectively, the most
frequently mutated genes were ASXL1 (14 cases= 47%),
TET2 (11 cases= 37%), RUNX1 (8 cases= 27%) and
SRSF2 (5 cases= 17%). Interestingly, all patients showing the
single SRSF2 mutation evolved to AML, while all patients
without any somatic myeloid gene mutation had a favorable
response (CR or HI) and did not progress into AML.
Inositide-specific gene mutation analyses
Paired samples (pre- and post-treatment) were also tested
for other 31 genes, chosen among the inositide-specific
signalling pathways (Supplementary Table 3). Eight genes
showed no baseline mutations and did not acquire any
variant during the therapy (PRKCA, GSK3A, GSK3B,
MZF1, MYB, NFKB1, CDKN2B, and SLC29A2), whereas
SOD2 and HFE genes showed no mutations at baseline but
acquired variants during the therapy.
At baseline, 21/31 genes were mutated, with MAP2K3
gene showing 95 variants. During the treatment, 19/31
genes acquired specific variants: MTOR, PIK3CA, PIK3R1,
TNF, SOD2, MAP2K1, PLCG2, MAP2K3, MAP2K2,
PLCB1 at T4, and PIK3CD, MTOR, AKT3, MAP3K1,
2280 M. Y. Follo et al.
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PIK3R1, HFE, CDKN1A, SOD2, AKT1, PLCG2,
MAP2K3, MAP2K2, PIK3R2, PLCB1, PLCG1, RPS6KA3
at T8 (Supplementary Table 3). As shown in Fig. 1, in TR
and NR patients, there was a significant increased VAF
during therapy, as compared to baseline, with the acquisi-
tion of 233 specific variants at T8 in TR patients and 83 in
NR patients. Interestingly, these two groups also showed a
low number of variants at baseline: 4 in TR patients,
affecting MAP2K2, CYPD26, and RPS6KA3 genes, and 8
in NR patients, affecting MAP3K1, PLCG2, MAP2K3,
PLCB1 and RPS6KA3 genes. Therefore, VAF increased by
58 times in TR patients and 10 times in NR patients, as
compared to baseline.
Identification of a 3-gene cluster associated with
loss of response
The SIFT score [53] was used to further analyze the
mutation profile: 11 genes (6 only at T8 and 5 both at T4
and T8) were mutated in TR patients, while 7 genes (6 only
at T8 and 1 only at T4) were mutated in NR patients
(Fig. 2). On the contrary, in all patients responding to the
treatment at T8 (including both GR and LR), only 3 genes
(SOD2, PLCG2, PIK3CD) acquired specific common
mutations at T4 and T8 (Fig. 2).
Interestingly, in both TR and NR patients, there was a
common specific cluster of 6 mutated genes (MAP2K1,
PIK3CD, RPS6KA3, AKT3, PIK3CG, PLCG2), detected as
88 variants in TR patients and 34 variants in NR patients
(Fig. 2). A depth analysis of these variants not only showed
that 3 genes (PIK3CD, AKT3, and PLCG2) were com-
monly altered at T8 in both these two groups but, more
interestingly, the same 3 point mutations were acquired:
D133E in PIK3CD gene, D280G in AKT3 gene, and
Q548R in PLCG2 gene (Fig. 3). Interestingly, the sequence
analysis of these point mutations revealed that the mutation
affecting AKT3 was included in the catalytic domain of
AKT3, while PLCG2 mutation was located within the
Fig. 1 Inositide-Specific
mutated variants in MDS
patients at baseline, at the 4th
cycle (T4) and at the 8th cycle
(T8) of azacitidine and
lenalidomide therapy. Venn
diagram showing the global
number of mutated variants in:
a all patients analyzed, b Good
Responders, c Transient
Responders, d Non Responders
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N-terminal Src homology 2 (N-SH2) - phosphotyrosine
binding pocket domain (Fig. 3).
Survival analyses
As reported in Fig. 4, the association between SRSF2
mutations and OS was close to significant: 30 vs 12 months
with 95% CI +2.15 to +2.84, p= 0.05; HR= 0.25 with
95% CI +0.06 to +1.04. Also the association between
SRSF2 mutations and LFS was close to significant: 28 vs
9 months with 95% CI +2.76 to +3.45, p= 0.05; HR=
0.24 with 95% CI +0.06 to +1.02. On the contrary, SRSF2
mutations were not significantly associated with duration of
response: 28 vs 14.5 months with 95% CI +1.64 to +2.21;
p= 0.11; HR= 0.27 with 95% CI +0.06 to +1.35. On the
other hand, the presence of our inositide-mutated 3-gene
cluster was significantly associated with a shorter OS (35 vs
15 months with 95% CI +1.84 to +2.81, p= 0.046; HR=
0.24 with 95% CI +0.09 to +0.64), a shorter LFS (28 vs
13.5 months with 95% CI +1.58 to +2.56, p= 0.0011;
HR= 0.19 with 95% CI +0.07 to +0.52) and a shorter
duration of response (16 vs 5 months with 95% CI +2.78 to
+3.62, p= 0.0012; HR= 0.09 with 95% CI +0.02 to
+0.38).
Discussion
Azacitidine alone is a standard therapy for MDS patients at
higher risk of AML evolution, while lenalidomide is widely
used in MDS with del(5q) deletion. The combination of
azacitidine and lenalidomide has been clinically investi-
gated, but the molecular effect of this treatment on mutation
profiling is still not well known, although the extent of
genetic rearrangements has been associated with outcome
and response to treatment [54]. Moreover, as a reliable
clinical evaluation of the combination therapy effect is
possible only after several cycles of therapy, the identifi-
cation of predictive molecular markers of response/resis-
tance would be very helpful, above all because the
persistence of mutated subclones can influence the response
to epigenetic therapy [55].
Nuclear inositides are involved in hematopoietic differ-
entiation and in MDS pathogenesis, genetically and epi-
genetically. Indeed, the presence of a PI-PLCbeta1
mono-allelic deletion in MDS patients has been associated
with a higher probability of AML evolution [56]. On the
other hand, PI-PLCbeta1 is also a specific target and a
dynamic predictive marker of azacitidine effect, either
positive or negative, in MDS patients [32, 33].
Fig. 2 Inositide-Specific mutated genes according to the SIFT score in
MDS patients at baseline, at the 4th cycle (T4) and at the 8th cycle
(T8) of azacitidine and lenalidomide therapy. Venn diagram showing
the global number of mutated genes, divided according to the SIFT
score, in: a all patients analyzed, b Good Responders, c Transient
Responders, d Non Responders. The bottom part of the Figure shows
the genes acquiring specific mutations during the therapy in: e all
patients analyzed (common T4 and T8, n= 1), f GR patients (common
T4 and T8, n= 3), g TR patients (common T4 and T8, n= 5; T8 only,
n= 6), h NR patients (T8 only, n= 6), clustered according to the SIFT
score: gray squares indicate no mutation, green to red squares indicate
a lower to higher probability of impaired protein function due to
mutation
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In this study we investigated the molecular mechanisms
underlying azacitidine and lenalidomide therapy, focusing
on the mutation profile of cancer myeloid genes (i.e.,
ASXL1, RUNX1, TET2, IDH1/2) as well as a selection of
inositide-related genes, known to be involved in survival
pathways (i.e., PI3K/Akt/mTOR, RAS/MAPK), hemato-
poietic differentiation (i.e., protein kinase C alpha, PI-
PLCgamma2) [21], cell cycle (i.e., CDKN2B, protein
kinase C alpha) [57] or drug metabolism (i.e., RPS6KA3,
SOD2, CYP2D6, SLC29A2). In particular, we analyzed the
mutation profile of MDS samples at baseline and during the
combination therapy (possibly both at T4 and T8) and
correlated it with clinical outcome, OS, LFS, and response
to therapy.
In our patient cohort, three patients did not show any
myeloid gene mutation neither at baseline nor during ther-
apy: they all had a favorable response (CR or HI) and did
not progress into AML. In contrast, all remaining patients
showed at least one myeloid-related mutation at baseline
and maintained it during the therapy, although showing
different VAFs according to the clinical response. Indeed,
all samples showing a decreasing VAF during therapy, as
compared to baseline levels, had a favorable response
(mainly CR, mCR or PR), while none of the nonresponders
showed a decreasing VAF. Collectively, the most fre-
quently mutated cancer myeloid genes were ASXL1 (47%),
TET2 (37%), RUNX1 (27%) and SRSF2 (17%). Interest-
ingly, all patients showing the single SRSF2 mutation
Fig. 3 Common point mutations affecting 3 inositide-specific genes in
MDS patients early losing response and never responding to azaciti-
dine and lenalidomide therapy. Domain structure of a PIK3CD,
b AKT3, and c PLCG2 proteins, along with the sequence domains
affected by gene mutations: the mutated amino acids are highlighted in
pink. Amino acids already known to be implicated in protein function
are highlighted in yellow. Abbreviations: BD: binding domain; C2:
calcium-binding domain; HD: hydrophobic regulatory domain; PH,
Pleckstrin-homology domain; X-Box: phosphatidylinositol-specific
phospholipase C X domain; SH2: Src homology 2 domain; SH3:
Src homology 3 domain; Y-Box: phosphatidylinositol-specific phos-
pholipase C Y domain
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evolved to AML, although the association between the
presence of SRSF2 mutations and the LFS was close to
significant (p= 0.05). This could be due to the low number
of cases analyzed so far, but is still indicative of a negative
correlation that needs to be investigated, also in the light of
recent data from AML patients showing that SRSF2 per-
sisting mutations are associated with a higher cumulative
incidence of relapse [58].
As for the inositide-specific genes, 8 genes never showed
mutations, neither at baseline nor during therapy: PRKCA,
GSK3A, GSK3B, MZF1, MYB, NFKB1, CDKN2B, and
SLC29A. Interestingly, this cluster included genes involved
in inositide metabolism (PRKCA), cell cycle regulation
(CDKN2B) and myeloid differentiation (MZF1 and MYB).
On the other hand, 21/31 genes showed mutations at
baseline and during the treatment, and 19/31 genes acquired
specific variants. Collectively, there was a significant
increased VAF during therapy in TR or NR patients, that
showed an increased number of acquired mutations at T8.
Moreover, these two groups also showed the lowest number
of variants at baseline: 4 in TR patients, affecting MAP2K2,
CYPD26, and RPS6KA3 genes, and 8 in NR patients,
affecting MAP3K1, PLCG2, MAP2K3, PLCB1, and
RPS6KA3 genes.
A deeper analysis of the inositide-specific mutation
profile, performed by using the SIFT score [53], that pre-
dicts the effect of a point mutation on the protein function,
revealed a small cluster of 6 genes commonly mutated only
in TR and NR patients: MAP2K1, PIK3CD, RPS6KA3,
AKT3, PIK3CG, and PLCG2. More interestingly, 3 of these
genes (PIK3CD, AKT3, and PLCG2) acquired the same 3
point mutations: D133E in PIK3CD gene, D280G in AKT3
gene, and Q548R in PLCG2 gene. The analysis of the
amino acid characteristics, as well as the examination of
the protein sequence, revealed that D to E substitution is
quite common, as both amino acids are quite frequently
involved in protein active or binding sites and, in certain
cases, they can also perform a similar role in the catalytic
site of proteases or lipases. Moreover, this amino acid
change, affecting PIK3CD gene, is located at the N-terminal
and does not affect any known domain.
On the other hand, the D280G and Q548R mutations
could affect amino acid polarization (thus possibly protein
structure and function), in that D is negatively charged, G
and Q have no charge and R is positively charged. More-
over, both AKT3 and PLCG2 point mutations localize
within important protein domains: the catalytic domain of
AKT3 and the N-terminal Src homology 2 (N-SH2)—
phosphotyrosine binding pocket domain of PLCG2,
although affecting amino acids not yet known to be
important for protein function. Nevertheless, as both D and
Q amino acids are quite frequently involved in protein
active or binding sites, the mutations we retrieved might be
associated with an impaired enzyme activity or protein
stability. Indeed, the D to G substitution in AKT3 gene is
usually a disfavoured one, in that it can affect protein
conformation, increasing the conformational flexibility and
using the G backbone to bind to phosphates. Moreover,
AKT3 mutations affecting the catalytic kinase domain have
been associated with elevated kinase activity in brain
Fig. 4 Kaplan–Meier estimates of overall survival, leukemia-free
survival, and duration of response in MDS patients treated with aza-
citidine and lenalidomide. a Patients are stratified according to the
presence of SRSF2 mutation (SRSF2) or the absence of SRSF2
mutation (NO MUT). b Patients are stratified according to the presence
of our 3-inositide gene mutation (CLUSTER) or the absence of our 3-
inositide gene mutation (NO MUT). *p < 0.05 CLUSTER vs NO MUT
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diseases [59], thus impacting the enzyme activity. Also the
Q to R substitution is linked to protein stability, as both Q
and R generally prefer to be on the surface of the proteins,
but R make multiple hydrogen bonds with the phosphate,
especially in SH2 domains [60].
Remarkably, the presence of our inositide-mutated 3-
gene cluster (PIK3CD, AKT3, and PLCG2) was sig-
nificantly associated with a shorter OS, a shorter LFS and a
shorter duration of response, possibly predicting the unfa-
vorable effect of azacitidine and lenalidomide combination
therapy in MDS patients. Furthermore, as PIK3CD and
AKT3 genes are actively involved in cell proliferation, it is
likely that the acquisition of these specific point mutations
in MDS not responding to therapy could give a proliferative
advantage to mutated cells. On the other hand, as PLCG2
has been associated with myeloid differentiation, it is also
likely that the acquisition of our specific point mutation in
non responder MDS patients could result in an impaired
hematopoietic differentiation that leads to a stable disease or
AML progression.
All in all, our data confirm the results of previous studies
[21, 22], in that also in this study inositides were associated
with MDS. Here, PIK3CD, AKT3, and PLCG2 point
mutations were correlated to and anticipated a negative
clinical outcome, as all of the MDS patients included in this
study that acquired the mutated cluster were also refractory
to azacitidine and lenalidomide therapy at T8. Although this
is a preliminary analysis, performed on a relatively small
number of cases, the statistically significant association
between this cluster and a shorter OS, LFS, and duration of
response pave the way to larger studies.
To our knowledge, this is the first time that a systematic
mutation analysis of inositide-related genes during azaciti-
dine and lenalidomide therapy in MDS has been performed.
More importantly, our findings indicate that a specific
mutated 3-gene cluster is associated with early loss of
response or refractoriness.
Given the involvement of nuclear inositides in cell cycle
and in hematopoietic differentiation, and on the basis of our
results, we feel that further investigating the effect of these
point mutations on protein function could be important to
understand the basic and translational implications of these
mutations, to find alternative strategies aiming to activate
specific signalling pathways to induce cancer cell apoptosis
and/or normal myeloid differentiation in MDS.
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